10-KPeriod: FY2022

ELI LILLY & Co Annual Report, Year Ended Dec 31, 2022

Filed February 22, 2023For Securities:LLY

Summary

Eli Lilly and Company (LLY) reported strong performance in its 2022 10-K filing, with total revenue reaching $28.54 billion, a slight increase from the previous year, driven by volume growth in key products like Trulicity, Verzenio, Jardiance, and Taltz. The company's profitability also saw a notable increase, with net income rising 12% to $6.24 billion. This growth was underpinned by robust clinical development progress, particularly in areas like diabetes with Mounjaro and cardiovascular disease. Despite facing patent expirations for some older products like Alimta, which led to significant revenue declines in those segments, Lilly demonstrated resilience through its strong pipeline and successful launches of newer, high-growth products. The company is heavily investing in research and development, with R&D expenses increasing to $7.19 billion, reflecting its commitment to innovation in therapeutic areas such as obesity, immunology, neuroscience, and oncology. Lilly is also strategically expanding its manufacturing capabilities to meet strong demand for its incretin products. While the company faces ongoing challenges from generic competition, pricing pressures, and evolving regulatory landscapes (including the Inflation Reduction Act), its strategic focus on innovation, pipeline development, and operational efficiency positions it for continued growth and value creation for shareholders.

Financial Highlights

53 data points
Beta

Revenue

$28.54B

76.8% Gross Margin

Net Income

$6.24B

21.9% Net Margin

EPS (Diluted)

$6.90

Total Assets

$49.49B

Cash & Equivalents

$2.07B

Free Cash Flow

$7.59B

Financial Statements
Beta
Revenue$28.54B
Cost of Revenue$6.63B
Gross Profit$21.91B
R&D Expenses$7.19B
SG&A Expenses$6.44B
Interest Expense$331.60M
Net Income$6.24B
EPS (Basic)$6.93
EPS (Diluted)$6.90
Shares Outstanding (Basic)901.74M
Shares Outstanding (Diluted)904.62M

Key Highlights

  • 1Total revenue for 2022 was $28.54 billion, a 1% increase year-over-year, primarily driven by volume growth in key products.
  • 2Net income increased by 12% to $6.24 billion, indicating improved profitability.
  • 3Research and development expenses increased by 4% to $7.19 billion, reflecting significant investment in pipeline development.
  • 4Key products like Trulicity, Verzenio, Jardiance, and Taltz showed strong revenue growth, contributing significantly to the top line.
  • 5The launch of Mounjaro for type 2 diabetes shows promising uptake, with ongoing Phase II trials for obesity.
  • 6The company is actively expanding manufacturing capacity to meet increasing demand for its incretin products.
  • 7Revenue from Alimta significantly declined due to generic competition following patent expirations.

Frequently Asked Questions

Eli Lilly's financial performance in 2022 was primarily driven by increased sales volume for its key products such as Trulicity, Verzenio, Jardiance, and Taltz. While overall revenue saw a modest increase to $28.54 billion, net income grew by a more substantial 12% to $6.24 billion, indicating improved operational efficiency and profitability. The company's significant investment in R&D, totaling $7.19 billion, also fueled future growth prospects.

Eli Lilly is strategically managing patent expirations, such as for Alimta, by focusing on its robust pipeline of newer, innovative medicines like Mounjaro and Verzenio. The company experienced a significant revenue decline for Alimta due to generic competition after patent expiries in key markets. To counteract this, Lilly continues to invest heavily in R&D to develop and launch new products that can offset these declines and drive future revenue growth.

Eli Lilly is experiencing strong demand for its incretin products, including Trulicity and Mounjaro, and is actively investing in expanding its manufacturing capacity globally to meet this demand. The company anticipates that tight supplies will persist until new manufacturing capacity becomes fully operational, with significant expansions expected in 2023 and beyond. This expansion is crucial to capitalize on the significant demand for these medicines.

The Inflation Reduction Act (IRA) introduces provisions that could impact Eli Lilly, particularly its pricing and reimbursement strategies. The IRA will allow the U.S. government to set prices for certain Medicare Part B and Part D drugs starting nine or thirteen years after initial FDA approval. While the specific impact is still unfolding, it could lead to accelerated revenue erosion for some of Lilly's significant products before patent expiry. The company is closely monitoring the IRA's implementation and its potential effects on its business strategies.